IGM Biosciences (IGMS) Competitors $1.36 0.00 (0.00%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.35 -0.01 (-1.03%) As of 07/11/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IGMS vs. AVTE, AVIR, DBVT, ANNX, OLMA, RCKT, CMPS, AARD, ABEO, and GLUEShould you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Aerovate Therapeutics (AVTE), Atea Pharmaceuticals (AVIR), DBV Technologies (DBVT), Annexon (ANNX), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), COMPASS Pathways (CMPS), Aardvark Therapeutics (AARD), Abeona Therapeutics (ABEO), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. IGM Biosciences vs. Its Competitors Aerovate Therapeutics Atea Pharmaceuticals DBV Technologies Annexon Olema Pharmaceuticals Rocket Pharmaceuticals COMPASS Pathways Aardvark Therapeutics Abeona Therapeutics Monte Rosa Therapeutics IGM Biosciences (NASDAQ:IGMS) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment. Do insiders and institutionals believe in IGMS or AVTE? 42.8% of IGM Biosciences shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is IGMS or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Aerovate Therapeutics' return on equity of -90.19% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-7,417.79% -317.97% -71.43% Aerovate Therapeutics N/A -90.19%-77.47% Which has more risk & volatility, IGMS or AVTE? IGM Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Does the media prefer IGMS or AVTE? In the previous week, IGM Biosciences had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for IGM Biosciences and 0 mentions for Aerovate Therapeutics. IGM Biosciences' average media sentiment score of 1.87 beat Aerovate Therapeutics' score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the media. Company Overall Sentiment IGM Biosciences Very Positive Aerovate Therapeutics Neutral Which has preferable earnings & valuation, IGMS or AVTE? Aerovate Therapeutics has lower revenue, but higher earnings than IGM Biosciences. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$2.68M30.34-$195.79M-$3.27-0.42Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-6.19 Do analysts rate IGMS or AVTE? IGM Biosciences currently has a consensus target price of $5.50, indicating a potential upside of 304.41%. Given IGM Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe IGM Biosciences is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryIGM Biosciences beats Aerovate Therapeutics on 9 of the 14 factors compared between the two stocks. Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IGMS vs. The Competition Export to ExcelMetricIGM BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.29M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-0.4220.5827.9620.25Price / Sales30.34292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book1.667.638.045.49Net Income-$195.79M-$55.05M$3.18B$250.27M7 Day Performance0.37%8.54%3.67%4.80%1 Month Performance12.40%5.51%4.09%7.68%1 Year Performance-85.89%2.03%29.58%16.36% IGM Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IGMSIGM Biosciences4.6162 of 5 stars$1.36flat$5.50+304.4%-85.4%$81.29M$2.68M-0.42190Positive NewsAVTEAerovate TherapeuticsN/A$11.14+3.1%N/A-84.0%$322.89MN/A-3.7320High Trading VolumeAVIRAtea Pharmaceuticals2.7259 of 5 stars$3.64-2.7%$6.00+64.8%+8.9%$320.07MN/A-2.2170News CoverageDBVTDBV Technologies3.9901 of 5 stars$11.01-5.1%$14.75+34.0%+174.4%$317.72M$4.15M-2.2480Gap UpANNXAnnexon2.5697 of 5 stars$2.73-5.5%$12.50+357.9%-52.8%$317.08MN/A-2.3160News CoverageOptions VolumeGap DownOLMAOlema Pharmaceuticals2.4193 of 5 stars$4.45-2.6%$24.50+450.6%-62.8%$312.68MN/A-2.2170RCKTRocket Pharmaceuticals4.8681 of 5 stars$2.81-3.1%$18.60+561.9%-86.5%$309.68MN/A-1.07240Trending NewsCMPSCOMPASS Pathways1.8185 of 5 stars$3.31+1.5%$17.00+413.6%-49.2%$305.01MN/A-1.66120AARDAardvark TherapeuticsN/A$13.92flat$33.00+137.1%N/A$302.01MN/A0.0018ABEOAbeona Therapeutics3.7728 of 5 stars$5.75-2.4%$19.25+234.8%+10.6%$301.31M$3.50M-4.5390Trending NewsInsider TradeGLUEMonte Rosa Therapeutics2.0357 of 5 stars$4.97+2.1%$15.33+208.5%+27.1%$299.55M$75.62M62.1390 Related Companies and Tools Related Companies AVTE Alternatives AVIR Alternatives DBVT Alternatives ANNX Alternatives OLMA Alternatives RCKT Alternatives CMPS Alternatives AARD Alternatives ABEO Alternatives GLUE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IGMS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IGMS Stock Alerts